JP2016506417A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506417A5 JP2016506417A5 JP2015552755A JP2015552755A JP2016506417A5 JP 2016506417 A5 JP2016506417 A5 JP 2016506417A5 JP 2015552755 A JP2015552755 A JP 2015552755A JP 2015552755 A JP2015552755 A JP 2015552755A JP 2016506417 A5 JP2016506417 A5 JP 2016506417A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- groups
- unsubstituted
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 36
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 20
- 238000000034 method Methods 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 210000001147 pulmonary artery Anatomy 0.000 claims 12
- 230000004872 arterial blood pressure Effects 0.000 claims 10
- 208000002815 pulmonary hypertension Diseases 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 229910052731 fluorine Inorganic materials 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000004104 aryloxy group Chemical group 0.000 claims 6
- 229910052794 bromium Inorganic materials 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- -1 guanidinyl groups Chemical group 0.000 claims 6
- 229910052740 iodine Inorganic materials 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 6
- 230000001965 increasing effect Effects 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 claims 4
- 102000012085 Endoglin Human genes 0.000 claims 4
- 108010036395 Endoglin Proteins 0.000 claims 4
- 206010020880 Hypertrophy Diseases 0.000 claims 4
- 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 claims 4
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 claims 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 230000009885 systemic effect Effects 0.000 claims 4
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 claims 3
- 206010021143 Hypoxia Diseases 0.000 claims 3
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 3
- 230000007954 hypoxia Effects 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 3
- 102100025422 Bone morphogenetic protein receptor type-2 Human genes 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 2
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 2
- 201000006306 Cor pulmonale Diseases 0.000 claims 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 2
- 208000015872 Gaucher disease Diseases 0.000 claims 2
- 101000934635 Homo sapiens Bone morphogenetic protein receptor type-2 Proteins 0.000 claims 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 2
- 241000257303 Hymenoptera Species 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010021133 Hypoventilation Diseases 0.000 claims 2
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 claims 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 2
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 206010049459 Lymphangioleiomyomatosis Diseases 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 2
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 claims 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000009905 Neurofibromatoses Diseases 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 206010071436 Systolic dysfunction Diseases 0.000 claims 2
- 208000024799 Thyroid disease Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 2
- 208000028831 congenital heart disease Diseases 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000009547 development abnormality Effects 0.000 claims 2
- 238000000502 dialysis Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000007345 glycogen storage disease Diseases 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000007475 hemolytic anemia Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 229940001447 lactate Drugs 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 230000004199 lung function Effects 0.000 claims 2
- 229940049920 malate Drugs 0.000 claims 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 201000004931 neurofibromatosis Diseases 0.000 claims 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 210000003492 pulmonary vein Anatomy 0.000 claims 2
- 230000009467 reduction Effects 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 201000004409 schistosomiasis Diseases 0.000 claims 2
- 238000010911 splenectomy Methods 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 229940095064 tartrate Drugs 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 206010065553 Bone marrow failure Diseases 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 108010078321 Guanylate Cyclase Proteins 0.000 claims 1
- 102000014469 Guanylate cyclase Human genes 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims 1
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 claims 1
- 208000021085 Pulmonary hypertension with unclear multifactorial mechanism Diseases 0.000 claims 1
- 108091005682 Receptor kinases Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 230000037147 athletic performance Effects 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000009084 cardiovascular function Effects 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 230000023753 dehiscence Effects 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 1
- 208000007232 portal hypertension Diseases 0.000 claims 1
- 229940127293 prostanoid Drugs 0.000 claims 1
- 150000003814 prostanoids Chemical class 0.000 claims 1
- 230000009325 pulmonary function Effects 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000013220 shortness of breath Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 230000035488 systolic blood pressure Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361751217P | 2013-01-10 | 2013-01-10 | |
| US61/751,217 | 2013-01-10 | ||
| PCT/US2014/010773 WO2014110198A2 (en) | 2013-01-10 | 2014-01-09 | Therapeutic indications of kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016506417A JP2016506417A (ja) | 2016-03-03 |
| JP2016506417A5 true JP2016506417A5 (enExample) | 2016-04-14 |
Family
ID=51167503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552755A Pending JP2016506417A (ja) | 2013-01-10 | 2014-01-09 | キナーゼ阻害剤の治療指標 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20150352111A1 (enExample) |
| EP (1) | EP2988738A4 (enExample) |
| JP (1) | JP2016506417A (enExample) |
| AU (1) | AU2014205481A1 (enExample) |
| CA (1) | CA2897538A1 (enExample) |
| WO (1) | WO2014110198A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2675720T3 (es) * | 2013-01-10 | 2018-07-12 | Pulmokine, Inc. | Inhibidores de quinasa no selectivos |
| US9925184B2 (en) | 2013-10-11 | 2018-03-27 | Pulmokine, Inc. | Spray-dry formulations |
| EP4653015A3 (en) * | 2015-01-26 | 2025-12-31 | Yale University | COMPOSITIONS AND METHODS OF USE OF TYROSINE KINASE INHIBITORS |
| CA3041679A1 (en) | 2016-10-27 | 2018-05-03 | Lawrence S. ZISMAN | Combination therapy for treating pulmonary hypertension |
| US20200360477A1 (en) * | 2019-05-16 | 2020-11-19 | Aerovate Therapeutics, Inc. | Inhalable formulations for kinase inhibition |
| EP4247378A4 (en) * | 2020-11-23 | 2024-08-14 | Aerovate Therapeutics, Inc. | IMATINIB FORMULATIONS, MANUFACTURE AND USES THEREOF |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2486183C (en) * | 2002-05-23 | 2012-01-10 | Cytopia Pty Ltd. | Protein kinase inhibitors |
| AUPS251502A0 (en) * | 2002-05-23 | 2002-06-13 | Cytopia Pty Ltd | Protein kinase inhibitors |
| CA2545422C (en) * | 2003-12-03 | 2015-06-02 | Cytopia Research Pty Ltd | Tubulin inhibitors |
| WO2007087575A2 (en) * | 2006-01-24 | 2007-08-02 | University Of Chicago | Compositions and methods for treating pulmonary hypertension |
| BRPI0708347A2 (pt) * | 2006-02-28 | 2011-05-24 | Cytopia Res Pty Ltd | inibição jak2 como um tratamento da hipertensão arterial pulmonar |
| US8461161B2 (en) * | 2006-11-15 | 2013-06-11 | Ym Biosciences Australia Pty Ltd | Substituted pyrazines as inhibitors of kinase activity |
| ES2675720T3 (es) * | 2013-01-10 | 2018-07-12 | Pulmokine, Inc. | Inhibidores de quinasa no selectivos |
-
2014
- 2014-01-09 EP EP14737772.5A patent/EP2988738A4/en not_active Withdrawn
- 2014-01-09 WO PCT/US2014/010773 patent/WO2014110198A2/en not_active Ceased
- 2014-01-09 AU AU2014205481A patent/AU2014205481A1/en not_active Abandoned
- 2014-01-09 JP JP2015552755A patent/JP2016506417A/ja active Pending
- 2014-01-09 US US14/760,165 patent/US20150352111A1/en not_active Abandoned
- 2014-01-09 CA CA2897538A patent/CA2897538A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506418A5 (enExample) | ||
| JP2016506417A5 (enExample) | ||
| US20220008436A1 (en) | Treprostinil administration by inhalation | |
| CN1196479C (zh) | 吸入形式的苯并茚前列腺素制剂的用途 | |
| JP2025016462A (ja) | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター | |
| KR20160061994A (ko) | 바독솔론 메틸 또는 이의 유사체를 이용한 내피 기능장애의 치료 및 예방 방법 | |
| JP2014077003A5 (enExample) | ||
| JP2015526458A5 (enExample) | ||
| US20160166556A1 (en) | Methods of treating pulmonary hypertension | |
| US20190255080A1 (en) | Method of reducing thyroid-associated side effects | |
| US11141422B2 (en) | Methods for treating pulmonary hypertension | |
| JP2013237683A (ja) | 肺高血圧症の治療のためのロフルミラスト | |
| JP2025501309A5 (enExample) | ||
| JP2013528649A (ja) | 肺高血圧症の処置のために使用するためのラノラジン | |
| US20160287535A1 (en) | Uses and Methods for the Treatment of Liver Diseases or Conditions | |
| WO2004017993A1 (en) | Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension | |
| US20250073208A1 (en) | Il-6 and/or il-1beta inhibitor | |
| US20260000647A1 (en) | Compositions, Formulations, And Methods Of Treating Neurodegenerative Diseases | |
| TWI889805B (zh) | 器官損傷的預防和治療 | |
| Blythe et al. | Pulmonary hypertension and selective pulmonary vasodilators in acute lung injury | |
| Dabrowski et al. | Volatile anaesthetics reduce serum S100β concentrations in patients undergoing elective cardiac surgery | |
| Lango et al. | High-volume hemofiltration as adjuvant therapy for refractory shock after pericardiocentesis | |
| CN106692976A (zh) | P‑糖蛋白抑制剂Gelucire44/14作为经口服的盐酸小檗碱吸收促进剂的应用 | |
| EP1213019A2 (en) | Method for treating chronic obstructive pulmonary disease |